2002 Achievements
Secondary offering ($91M net)
SYMLIN™ titration study initiated and enrolled
AC2993 global collaboration signed with Lilly
AC2993 open-label study initiated and data reported
Humatrope® co-promotion sales force recruited
AC162352 (PYY [3-36]) designated as preclinical candidate
GLP-1 Phase 2 cardiovascular program acquired
AC2993 AMIGO program enrollment completed (~1600 patients)